Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy

Vertebral bone marrow fat fraction (BMFF) has been shown to be related to age, anatomical location, hormone levels as well as a variety of medical conditions or treatments, such as osteoporosis [1‐6], diabetes [4, 7, 8], radiation therapy and chemotherapy [9, 10]. In the context of osteoporosis, it has been established that bone loss is associated with an increase in vertebral BMFF [11‐13]. The altered differentiation of mesenchymal progenitor cells is one of several mechanisms on the cellular level causing this increase. These cells can differentiate into osteoblasts and osteocytes or into adipocytes. It was shown that with aging there is a shift to a more adipogenic fate [14].

Chemical shift encoded magnetic resonance imaging (CSE-MRI) and magnetic resonance spectroscopy (MRS) constitute two techniques that enable non-invasive in-vivo measurement of vertebral BMFF [15]. Previous studies have shown that proton density fat fraction (PDFF) is the parameter of choice when it comes to the assessment of vertebral bone marrow water-fat composition [16, 17].

Aromatase inhibitor (AI) therapy is a standard treatment component for estrogen receptor positive breast cancer in postmenopausal women [18‐20]. By reducing estrogen levels, it inhibits tumor cell growth. However, reduced estrogen levels also promote bone loss and the development of osteoporosis. To counteract this adverse drug effect, bisphosphonates (BP) can be administered which are recommended as first line antiosteoporotic therapy [21, 22] and have been shown to increase bone mineral density (BMD) [23], reduce fracture risk [24] and reduce BMFF [25] in postmenopausal osteoporotic women. The current clinical gold standard to assess osteoporosis-associated fracture risk in these patients is the determination of BMD using dual-energy X-ray absorptiometry (DXA). However, DXA-based BMD values of subjects with and without osteoporotic fractures overlap [26]. Therefore, advanced imaging biomarkers are needed to improve the prediction of fracture risk beyond BMD.

The purpose of the present study was to quantify changes in vertebral BMFF and BMD over one year in postmenopausal breast cancer patients receiving AI therapy with and without additional BP therapy, respectively. We hypothesized that vertebral BMFF measurements are more sensitive to medication induced changes than DXA-based BMD measurements.

Baseline age, BMI, BMD, and PDFF showed no significant (p > 0.05) difference between the AI+BP and AI-BP group. Similarly, these parameters were not significantly different between the two treatment groups at 12-month follow-up (Tab. 1 and 2, p > 0.05).

There was a positive ∆rel_PDFF averaged over L1 to L5 in both groups (AI+BP: 5.93%; AI-BP: 3.11%), however it was only significant (p = 0.006) in the AI+BP group. ∆rel_PDFF showed no significant difference between the two groups. There was no significant longitudinal change in BMD (Tab. 3). There was no significant (p > 0.05) correlation between PDFF and BMD for the entire patient group or any of the two treatment groups at baseline or follow-up.

Figure 2 demonstrates exemplary baseline and follow-up PDFF maps of representative subjects of both treatment groups.

The present study performed BMFF measurements at the lumbar spine of postmenopausal breast cancer patients over a 12-month period using CSE-MRI. In contrast to subjects receiving AI only, the vertebral bone marrow PDFF significantly increased in subjects receiving combined AI and BP therapy.

Vertebral bone marrow water-fat composition has been shown to be significantly altered in osteoporosis and therefore been proposed as advanced imaging biomarker for fracture risk prediction [28, 29]. The loss of trabecular bone in postmenopausal women is primarily caused by estrogen deficiency. Therefore, one important side effect of AI therapy is the promotion of bone loss which can be counteracted by the administration of BP. The present study found that vertebral bone marrow PDFF significantly increased from 45.66 to 48.40% in subjects receiving combined AI and BP therapy based on CSE-MRI measurements. This absolute change of 2.74% is higher than the previously reported reproducibility error of vertebral BMFF measurements of 1.7% [27]. Our findings are at odds with results from previous studies investigating the effect of BP therapy on BMFF quantified by MRS [25] as well as bone biopsies [30]. Those studies reported a significant reduction of BMFF in postmenopausal women receiving BP therapy. However, the two mentioned studies only investigated the effect of BP treatment on bone marrow adiposity in postmenopausal women not receiving any additional medication. In the literature, there is no previous study investigating the effect of BP therapy on postmenopausal women simultaneously receiving AI therapy. Although the detailed physiological and biochemical pathways are still not completely understood it is well established that estrogen is important for maintaining BMD. The protective effects of estrogen on bone health can be explained by several mechanisms. It stimulates osteoclast apoptosis and suppresses osteoblast and osteocyte apoptosis and thereby increases the lifespan of bone building cells and decreases the lifespan of bone resorbing cells. Furthermore, estrogen represses pro-osteoclastic cytokines, such as TNFα, IL-1, IL-6 and IL-7 and down-regulates osteoclastogenesis via the RANKL pathway [31, 32]. It has been shown that the effects of estrogen on bone cells are mediated via estrogen receptors ERα and ER​β. Interestingly, ERα is expressed at a higher level in cortical bone and ERβ is expressed at a higher level in trabecular bone [32]. Estrogen has also been shown to have effects on adipogenesis through regulation of adipocyte precursor proliferation and expression of adipocyte differentiation factors [33‐36].

It becomes clear that by reducing estrogen synthesis AI therapy decreases BMD resulting in impaired bone health. BP have been shown to enhance osteoclast apoptosis and thus decrease their lifespan [37, 38] as well as increase osteoblast lifespan [39]. Thus, the cellular and molecular pathways through which AI and BP affect bone turnover as well as bone marrow composition overlap to some extent, but are not completely identical. This could be a potential explanation why BP therapy has a different effect on patients receiving AI therapy than on patients not receiving any estrogen suppressing therapy.

We observed a significant longitudinal difference in vertebral bone marrow PDFF without corresponding changes in BMD. This could be attributed to the fact that vertebral bone marrow fat content not only depends on osseous changes, but also changes in bone marrow composition itself. A second concomitant explanation might be that bone marrow changes start to occur earlier than bone mass related changes. Our findings suggest a higher sensitivity of PDFF measurements to medication induced changes than DXA-based BMD. The fact that there was a close to significant BMD increase in the patient group receiving AI and BP therapy potentially implicates that the effect of BP on BMD is stronger than on PDFF. This can be considered additional evidence that osteoporosis related BMFF changes are not exclusively a result of the replacement of bone by adipose tissue.

The present study is not without limitations. There was no group of age-matched healthy controls. Since aging itself is a contributing factor for bone loss and increased bone marrow adiposity, in particular in postmenopausal women, such a control group would be beneficial in order to better assess the effects of AI und BP therapy. However, in [40] mean and standard deviation of lumbar VBM PDFF values of healthy female subjects of different age groups were analyzed. There was an increase in PDFF from 48.8 ± 7.7% to 50.5 ± 8.2% between the sixties and seventies age group, amounting to a relative PDFF increase of 3.5%, over a 10-year period of time. Admittedly, considering this data as a reference is not equivalent to a dedicated age-matched healthy control group. However, it should provide sufficient confidence that, firstly, the baseline PDFF values of the present study are within the range of healthy controls and, secondly, the 12-month longitudinal effects on marrow adiposity observed in the present study are not only the result of aging.

Another limitation of the present study is the relatively small sample size as well as the relatively short observation period. Performing future follow-up measurements will improve the assessment of treatment associated changes over a longer period of time. This could help to better characterize effects of combined AI and BP therapy on vertebral PDFF and reveal longer-term longitudinal effects.

Over a 12-month period vertebral PDFF assessed with CSE-MRI significantly increased in subjects receiving combined AI and BP therapy. The present results are not in line with previous results regarding the effect of only BP therapy on BMFF. However, there is no previous study on the combined effect of AI and BP therapy on BMFF. Performing additional follow-up measurements to assess longitudinal effects over a longer time period might help to further characterize the longer-term effects of combined AI and BP therapy on vertebral PDFF.